| abstract |
The invention relates to benzoylguanidines of the formula I (see Formula I) where R(1) is H, Hal, -NO2, -C.ident.N, -X o-(CH2)p-(CF2)q-CF3, R(5)-SO m, R(6)-CO-, R(6)R(7)N-CO- or R(6)R(7)N-SO2-, where X is oxygen, S or NR(14), m is zero. 1 or 2, o is zero or 1, p is zero, 1 or 2, q is zero, 1, 2. 3, 4, 5 or 6, R(5) and R(6) are alk(en)yl, -C n H2n-R(8) or CF3, n is zero, 1, 2, 3 or 4, R(8) is cycloalkyl or phenyl, where R(6) also has the meaning of H, R(7) is H or alkyl; R(2) is (see Formula II) R(11) is (C1-C9) -heteroaryl, Y is oxygen, -S- or NR(12)-, R(12) ie H or (C1-C4)- alkyl; R(3) is defined as R(1), or is alkyl or -X-R(13) where X is oxygen, S or NR(14), R(14) is H or (C1-C3)-alkyl, R(13) is H, (cyclo)alkyl or -C b H2b-R(15) where b is zero to 4 and R(15) is phenyl; R(4) is hydrogen, -OR(16), -NR(16)R(17) or C r B2r+1 where R(16) and R(17) independently are hydrogen or (C1-C3)-alkyl, r is 1 - 4 as well as pharmaceutically tolerated salts thereof. The compounds I are outstandingly suitable as anti-arrhythmic pharmaceuticals having a cardioprotective component for the prophylaxis and treatment of infarction and for the treatment of angina pectoris. |